These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23237488)

  • 21. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C.
    Lima-Cabello E; García-Mediavilla MV; Miquilena-Colina ME; Vargas-Castrillón J; Lozano-Rodríguez T; Fernández-Bermejo M; Olcoz JL; González-Gallego J; García-Monzón C; Sánchez-Campos S
    Clin Sci (Lond); 2011 Mar; 120(6):239-50. PubMed ID: 20929443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dietary phosphate restriction induces hepatic lipid accumulation through dysregulation of cholesterol metabolism in mice.
    Tanaka S; Yamamoto H; Nakahashi O; Kagawa T; Ishiguro M; Masuda M; Kozai M; Ikeda S; Taketani Y; Takeda E
    Nutr Res; 2013 Jul; 33(7):586-93. PubMed ID: 23827134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissection of the insulin-sensitizing effect of liver X receptor ligands.
    Commerford SR; Vargas L; Dorfman SE; Mitro N; Rocheford EC; Mak PA; Li X; Kennedy P; Mullarkey TL; Saez E
    Mol Endocrinol; 2007 Dec; 21(12):3002-12. PubMed ID: 17717069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ.
    Kick E; Martin R; Xie Y; Flatt B; Schweiger E; Wang TL; Busch B; Nyman M; Gu XH; Yan G; Wagner B; Nanao M; Nguyen L; Stout T; Plonowski A; Schulman I; Ostrowski J; Kirchgessner T; Wexler R; Mohan R
    Bioorg Med Chem Lett; 2015 Jan; 25(2):372-7. PubMed ID: 25435151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of liver X receptor-α-dependent hepatic steatosis by isoliquiritigenin, a licorice antioxidant flavonoid, as mediated by JNK1 inhibition.
    Kim YM; Kim TH; Kim YW; Yang YM; Ryu DH; Hwang SJ; Lee JR; Kim SC; Kim SG
    Free Radic Biol Med; 2010 Dec; 49(11):1722-34. PubMed ID: 20840863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice.
    Grefhorst A; van Dijk TH; Hammer A; van der Sluijs FH; Havinga R; Havekes LM; Romijn JA; Groot PH; Reijngoud DJ; Kuipers F
    Am J Physiol Endocrinol Metab; 2005 Nov; 289(5):E829-38. PubMed ID: 15941783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver X receptor modulators: a review of recently patented compounds (2009 - 2012).
    Loren J; Huang Z; Laffitte BA; Molteni V
    Expert Opin Ther Pat; 2013 Oct; 23(10):1317-35. PubMed ID: 23826715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of 5α, 6α-epoxycholesterol as a novel modulator of liver X receptor activity.
    Berrodin TJ; Shen Q; Quinet EM; Yudt MR; Freedman LP; Nagpal S
    Mol Pharmacol; 2010 Dec; 78(6):1046-58. PubMed ID: 20837678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.
    Wrobel J; Steffan R; Bowen SM; Magolda R; Matelan E; Unwalla R; Basso M; Clerin V; Gardell SJ; Nambi P; Quinet E; Reminick JI; Vlasuk GP; Wang S; Feingold I; Huselton C; Bonn T; Farnegardh M; Hansson T; Nilsson AG; Wilhelmsson A; Zamaratski E; Evans MJ
    J Med Chem; 2008 Nov; 51(22):7161-8. PubMed ID: 18973288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (RORγ)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand.
    Nishiyama Y; Nakamura M; Misawa T; Nakagomi M; Makishima M; Ishikawa M; Hashimoto Y
    Bioorg Med Chem; 2014 May; 22(9):2799-808. PubMed ID: 24702856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Skeletal muscle as a target of LXR agonist after long-term treatment: focus on lipid homeostasis.
    Archer A; Laurencikiene J; Ahmed O; Steffensen KR; Parini P; Gustafsson JÅ; Korach-André M
    Am J Physiol Endocrinol Metab; 2014 Mar; 306(5):E494-502. PubMed ID: 24368671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists.
    Griffett K; Hayes M; Bedia-Diaz G; Appourchaux K; Sanders R; Boeckman MP; Koelblen T; Zhang J; Schulman IG; Elgendy B; Burris TP
    ACS Chem Biol; 2022 May; 17(5):1143-1154. PubMed ID: 35417135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones.
    Hwahng SH; Ki SH; Bae EJ; Kim HE; Kim SG
    Hepatology; 2009 Jun; 49(6):1913-25. PubMed ID: 19378344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of tissue selective liver X receptor agonists for the treatment of atherosclerosis without causing hepatic lipogenesis.
    Li C; Chen H; Chen X; Li Y; Hua P; Wei J; Song C; Gu Q; Zhou H; Zhang J; Xu J
    Eur J Med Chem; 2019 Nov; 182():111647. PubMed ID: 31499362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice.
    Wouters K; van Bilsen M; van Gorp PJ; Bieghs V; Lütjohann D; Kerksiek A; Staels B; Hofker MH; Shiri-Sverdlov R
    FEBS Lett; 2010 Mar; 584(5):1001-5. PubMed ID: 20114046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors.
    Chen Z; Chen H; Zhang Z; Ding P; Yan X; Li Y; Zhang S; Gu Q; Zhou H; Xu J
    Eur J Med Chem; 2020 Nov; 206():112793. PubMed ID: 32961480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and Synthesis of a Novel Series of Liver X Receptor Antagonists.
    Nian S; Gan X; Tan X; Yu Z; Wang P; Chen X; Wang G
    Chem Pharm Bull (Tokyo); 2015; 63(8):628-35. PubMed ID: 26062802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and optimization of a series of liver X receptor antagonists.
    Jiao X; Kopecky DJ; Fisher B; Piper DE; Labelle M; McKendry S; Harrison M; Jones S; Jaen J; Shiau AK; Escaron P; Danao J; Chai A; Coward P; Kayser F
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5966-70. PubMed ID: 22901900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.